Preventive Medicine, Год журнала: 2025, Номер 192, С. 108240 - 108240
Опубликована: Фев. 3, 2025
Язык: Английский
Nature Human Behaviour, Год журнала: 2022, Номер 6(12), С. 1634 - 1648
Опубликована: Авг. 22, 2022
Язык: Английский
Процитировано
158
medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2022, Номер unknown
Опубликована: Янв. 2, 2022
The Omicron SARS-CoV-2 variant is rapidly spreading in the US since December 2021 and more contagious than earlier variants. Currently, data on severity of disease caused by compared with Delta limited. Here we 3-day risks emergency department (ED) visit, hospitalization, intensive care unit (ICU) admission, mechanical ventilation patients who were first infected during a time period when was emerging to those predominant. This retrospective cohort study electronic health record (EHR) 577,938 first-time from multicenter, nationwide database 9/1/2021-12/24/2021, including 14,054 had their infection 12/15/2021-12/24/2021 emerged ("Emergent cohort") 563,884 9/1/2021-12/15/2021 predominant ("Delta cohort"). After propensity-score matching cohorts, four outcomes (ED ICU ventilation) compared. Risk ratios, 95% confidence intervals (CI) calculated. Of Emergent (average age, 36.4 ± 24.3 years), 27.7% pediatric (<18 years old), 55.4% female, 1.8% Asian, 17.1% Black, 4.8% Hispanic, 57.3% White. differed significantly demographics, comorbidities, socio-economic determinants health. for health, medications vaccination status, consistently less half cohort: ED visit: 4.55% vs. 15.22% (risk ratio or RR: 0.30, CI: 0.28-0.33); hospitalization: 1.75% 3.95% (RR: 0.44, 0.38-0.52]); admission: 0.26% 0.78% 0.33, CI:0.23-0.48); ventilation: 0.07% 0.43% 0.16, 0.08-0.32). In children under 5 old, overall visits hospitalization 3.89% 0.96% respectively, lower 21.01% 2.65% matched (RR 0.19, 0.14-0.25; RR 0.36, 0.19-0.68). Similar trends observed other age groups (5-11, 12-17 adults (18-64 years) older (≥ 65 years). First infections occurring at associated severe predominated.
Язык: Английский
Процитировано
135
Expert Review of Vaccines, Год журнала: 2022, Номер 21(4), С. 435 - 451
Опубликована: Фев. 3, 2022
From July through October of 2021, several countries issued recommendations for increased COVID-19 vaccine protection individuals with one or more immunocompromised (IC) conditions. It is critically important to understand the effectiveness (VE) vaccines among IC populations as are updated over time in response evolving pandemic.
Язык: Английский
Процитировано
82
Nature Communications, Год журнала: 2022, Номер 13(1)
Опубликована: Янв. 20, 2022
Prior research using electronic health records for Covid-19 vaccine safety monitoring typically focuses on specific disease groups and excludes individuals with multimorbidity, defined as ≥2 chronic conditions. We examine the potential additional risk of adverse events 28 days after first dose CoronaVac or Comirnaty imposed by multimorbidity. Using a territory-wide public healthcare database population-based vaccination in Hong Kong, we analyze retrospective cohort patients Thirty special interest according to World Health Organization are examined. In total, 883,416 included 2,807 (0.3%) develop events. Results suggest vaccinated have lower risks than unvaccinated individuals, multimorbidity is associated increased regardless vaccination, association not modified To conclude, find no evidence that imposes extra following vaccination.
Язык: Английский
Процитировано
77
medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2022, Номер unknown
Опубликована: Фев. 22, 2022
SARS-CoV-2 infections and hospitalizations are rising in the US other countries after emergence of Omicron variant. Currently, data on infection rates, severity racial/ethnic gender disparities from is limited.
Язык: Английский
Процитировано
58
Vaccine, Год журнала: 2022, Номер 40(16), С. 2379 - 2387
Опубликована: Март 14, 2022
Язык: Английский
Процитировано
41
JAMA Network Open, Год журнала: 2023, Номер 6(1), С. e2251833 - e2251833
Опубликована: Янв. 20, 2023
Importance Immunocompromised individuals are at increased risk for severe outcomes due to SARS-CoV-2 infection. Given the varying and complex nature of COVID-19 vaccination recommendations, it is important understand vaccine uptake in this vulnerable population. Objective To assess mRNA factors associated with among immunocompromised from December 14, 2020, through August 6, 2022. Design, Setting, Participants This cohort study was conducted patients Kaiser Permanente Southern California (KPSC), an integrated health care system US. The included aged 18 years or older who were (individuals immunocompromising condition received immunosuppressive medications year prior 2020) still met criteria being 1 later. Exposures Age, sex, self-identified race ethnicity, positive test result, condition, immunomodulating medication, comorbidities, utilization, neighborhood median income. Main Outcomes Measures number doses receipt least 4 doses, estimated by hazard ratios (HRs) 95% Wald CIs via Cox proportional hazards regression. Statistical analyses between 9 23, Results Overall, 42 697 eligibility criteria. Among these, 789 (44.0%) 65 older; 20 061 (47.0%) women 22 635 (53.0%) men. With regard 4295 participants (10.1%) identified as Asian Pacific Islander, 5174 (12.1%) Black, 14 289 (33.5%) Hispanic, 17 902 (41.9%) White. As end period after accounting participant censoring death disenrollment KPSC plan, 78.0% had a third dose vaccine. Only 41.0% fourth dose, which corresponds primary series monovalent booster individuals. Uptake fifth only 0.9% following US Centers Disease Control Prevention (CDC) recommendation receive second (ie, dose). Adults (HR, 3.95 [95% CI, 3.70-4.22]) more likely compared those 44 45 64 (2.52 [2.36-2.69]). Hispanic non-Hispanic Black adults 0.77 0.74-0.80] 0.82 [0.78-0.87], respectively, White adults), documented infection (0.71 [0.62-0.81] without), receiving high-dose corticosteroids (0.88 [0.81-0.95] not) less doses. Conclusions Relevance These findings suggest that adherence CDC recommendations low. population well-established additional protection afforded targeted tailored efforts ensure remain up date warranted.
Язык: Английский
Процитировано
25
Supportive Care in Cancer, Год журнала: 2022, Номер 30(10), С. 7973 - 7982
Опубликована: Июнь 25, 2022
Abstract The psychosocial impact of coronavirus disease 2019 (COVID-19) on human life is well-known. Although vaccine protection represents an effective way to control the spread virus, vaccination hesitancy may decrease individuals’ willingness get vaccinated, including among cancer patients. Therefore, objective current study was examine predictors patients’ intentions receive COVID-19 vaccinations and uptake, using integrating theory planned behaviour (TPB) health belief model (HBM). A sample 276 Italian patients (54% female 46% male) ranging from 19 85 years ( M = 49.64, SD 11.53) recruited by administering online questionnaire. results showed that with higher trust in authorities tended have vaccine-positive subjective norms, perceived under their control, viewed vaccines positively. On other hand, risk related norms but not behavioural or attitudes towards vaccination. reveals TPB variables can function effectively as mediators between risk, trust, intention vaccinate at different levels. Together, these findings suggest interventions (both public messaging personal medical communications) should focus enhancing authorities, while same time endeavouring highlight are vaccine-positive.
Язык: Английский
Процитировано
30
Vaccine, Год журнала: 2023, Номер 41(7), С. 1303 - 1309
Опубликована: Янв. 20, 2023
People affected by diabetes are at higher risk for complications from certain vaccine-preventable diseases. Suboptimal vaccination coverages reported in this population sub-group. The purpose of study is to estimate the proportion diabetic patients who express hesitation COVID-19 vaccine worldwide.Seven studies were included meta-analysis and systematic review, selected scientific articles available MEDLINE/PubMed, Google Scholar Scopus databases 2020 2022. following terms used search strategy: (adherence OR hesitancy compliance attitude) AND (covid* SARS*) (vaccin* immun*) (diabet*).The rate among persons with was 27.8 % (95 %CI = 15.6-41.9 %). In comparison between sexes educational status, RRs 0.90 0.71-1.15) 0.88 0.76-1.02), respectively. main reasons unwillingness lack information, opinion that unsafe or not efficient, fear adverse events.In order achieve a high coverage, multifactorial approach needed, which requires major social, health efforts. success campaign depends on capillarity consistency interventions implemented.
Язык: Английский
Процитировано
19
Vaccines, Год журнала: 2021, Номер 9(10), С. 1097 - 1097
Опубликована: Сен. 28, 2021
COVID-19 has been spreading worldwide since late 2019. There is no definitive cure to date. Global vaccination programs are urgently required confer herd immunity, reducing the incidence of infections and associated morbidity mortality. However, a significant proportion special populations hesitant receive due their conditions, namely, age (pediatrics geriatrics), immunocompromised state, autoimmune diseases, chronic cardiovascular pulmonary active or treated cancers, pregnancy. This review aims evaluate existing evidence vaccinations on these provide clues guide decision making balance benefits risks vaccinations.
Язык: Английский
Процитировано
40